

**Sun Pharmaceutical Industries Limited**

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai – 400 063, Maharashtra, INDIA.  
Tel. : (91-22) 4324 4324  
Fax : (91-22) 4324 4343  
Website: [www.sunpharma.com](http://www.sunpharma.com)  
Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)  
CIN: L24230GJ1993PLC019050



September 28, 2023

**National Stock Exchange of India Ltd,**  
Exchange Plaza, 5th Floor, Plot No. C/1, G  
Block, Bandra Kurla Complex,  
Bandra (East), Mumbai – 400 051.  
**NSE Code – SUNPHARMA**

**BSE Ltd,**  
Market Operations Dept.  
P. J. Towers, Dalal Street,  
Mumbai - 400 001.  
**BSE Code– 524715**

**Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

This is to inform you that one of our subsidiary companies has signed a binding letter of intent to acquire the balance 25% outstanding shares of Sun Pharma de México, S.A. de C.V., a subsidiary of the Company, where the Company is currently holding 75% shares.

Post-acquisition of the balance 25% outstanding shares will result into Sun Pharma de México, S.A. de C.V. becoming a wholly-owned subsidiary of the Company.

The relevant details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, are provided as per **Annexure A**.

This is for your information and record.

Thanking you,

Yours faithfully,

**For Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)

**Company Secretary and Compliance Officer**

ICSI Membership No.: A23983

**Annexure A**

**Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

a) Name of the target entity, details in brief such as size, turnover etc.;	<ul style="list-style-type: none"><li>• Sun Pharma de México, S.A. de C.V., (“Target Company”) a company duly incorporated under the laws of the United Mexican States.</li><li>• Target Company is a subsidiary of Sun Pharmaceutical Industries Limited (“Sun Pharma”), wherein Sun Pharma holds 75% of the shares of the Target Company and the balance 25% is held by Indi Pharma S.A.P.I. de C.V. (“Local Partner”).</li><li>• The revenue from operations for FY2022* was MXN \$389.55 Million</li></ul> <p><i>*FY is January to December</i></p>
b) Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arms-length”;	No, the transaction is not a related party transaction and promoter / promoter group does not have any interest in the entity whose securities are being acquired.
c) Industry to which the entity being acquired belongs;	Pharmaceuticals
d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	<ul style="list-style-type: none"><li>• The acquisition enables Sun Pharma to acquire the balance 25% stake held by the Local Partner, in the Target Company.</li><li>• This acquisition will be done through a wholly-owned Subsidiary, Sun Pharma (Netherlands) B.V.</li><li>• Post this acquisition, the Target Company would become a wholly-owned subsidiary of Sun Pharma.</li></ul>
e) Brief details of any governmental or regulatory approvals required for the acquisition;	Not Applicable
f) Indicative time period for completion of the acquisition;	Acquisition is likely to be completed by 31 <sup>st</sup> October 2023

g) Consideration - whether cash consideration or share swap and details of the same;	Cash Consideration								
h) Cost of acquisition <del>or the price at which the shares are acquired;</del>	MXN \$161.85 Million								
i) Percentage of shareholding / control acquired and / or number of shares acquired;	Balance 25% shares in the Target Company resulting in 100% ownership of the Target Company.								
j) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p>The Target Company is engaged in the business of marketing and distribution of pharmaceutical products in Mexico.</p> <p>The Target Company was incorporated on 03<sup>rd</sup> December 2002</p> <p>The revenue from operations for previous three years is as follows,</p> <table border="1" data-bbox="764 1041 1438 1220"> <thead> <tr> <th data-bbox="764 1041 1084 1108"><b>FY (January to December)</b></th> <th data-bbox="1084 1041 1438 1108"><b>Turnover (in MXN \$)</b></th> </tr> </thead> <tbody> <tr> <td data-bbox="764 1108 1084 1146">2022</td> <td data-bbox="1084 1108 1438 1146">389.55 Million</td> </tr> <tr> <td data-bbox="764 1146 1084 1184">2021</td> <td data-bbox="1084 1146 1438 1184">344.65 Million</td> </tr> <tr> <td data-bbox="764 1184 1084 1220">2020</td> <td data-bbox="1084 1184 1438 1220">335.69 Million</td> </tr> </tbody> </table>	<b>FY (January to December)</b>	<b>Turnover (in MXN \$)</b>	2022	389.55 Million	2021	344.65 Million	2020	335.69 Million
<b>FY (January to December)</b>	<b>Turnover (in MXN \$)</b>								
2022	389.55 Million								
2021	344.65 Million								
2020	335.69 Million								